Researchers develop 'ready' immune treatment for any patient with kidney cancer

US researchers have announced the development of an innovative immune treatment that can be used directly to treat kidney cancer without assigning it separately to each patient. The new treatment, called Allocar70-NCT, is based on genetic engineering immune cells that can attack crops and reprogram the surrounding environment, a step that can change the rules of confrontation one of the most difficult treatment diseases in treatment. Despite the great progress of immune treatments and treated treatments in recent years, the distribution of gland of gland of renal cancer is still a fatal challenge; Many patients do not respond to treatment, or are exposed to regular setbacks, while the survival rate for 5 years is not just 12%. This dark reality has made the need urgent to innovate more effective and safe treatment strategies. The new treatment was designed in a radically different way; Researchers have transformed stem cells into NKT cells and are provided with industrial receptors known as CAR aimed at CD70 protein spread on the surface of kidney cancer cells. The researchers said that the most important feature is that these cells are not specific to a specific patient, but rather to use for any patient, bypassing the long-time obstacle and complications that impede traditional cellular treatments such as CAR-T. The traditional Car-T cell treatments are based on the principle of designing a personal treatment for each patient separately, and the process begins to extract T-cells from the patient’s blood, and then sends them to specialized laboratories where they are subject to a complex genetic modification process, which enables an industrial future, which enables the cells to make certain proteins on the surface identify cancer cells. This step alone requires high -cost techniques, takes days or weeks, and after modification cells are planted, and they are doubled in laboratory conditions until a sufficient number of it is obtained, and then later returned by the venous leak to the body’s body. The problem in this method is that the long period can be decisive and dangerous, as some patients with aggressive waiting cancer may not carry, and in addition, the quality of the extracted cells varies from one patient to another; Some patients are that their cells are exhausted or damaged due to the progress of the disease or due to previous treatments, reducing the effectiveness of treatment after the adjustment. In addition to the scientific and logistical complexity, there is another obstacle that is proposed in the high cost; Which reaches hundreds of thousands of dollars for each patient, as well as the need for advanced medical centers and specialized teams, and despite the remarkable successes of CAR-T in some blood cancer, the obstacle of time and complexity limits their distribution and is still difficult to apply in solid cancers such as kidney cancer. A three -dimensional attack that the researchers explained that they have managed to turn stem cells into strong immune cells that can fight cancer, and be given to any patient, without producing his own cells, and emphasizes that this method reduces the risks of traditional immune treatments, especially for patients in the late stages. The study published in cell reports showed that the treatment depends on a ‘three -dimensional attack’ against cancer, as it directly attacks the crop first, even in cases where the levels of CD70 protein are low, which is a traditional obstacle to the success of immune treatments. There is a CD70 protein on the surface of some cells, and is used as a ‘sign’ or ‘dating key’ that enables immune cells to identify the targeted cell; Many immune treatments, especially modified cells such as CAR-T, depend on the presence of this protein much on the surface of the cancer cells to accurately attack it. But the problem is that some crops do not show high levels of this protein, or that they can deliberately hide to escape the immune system, and these crops are sometimes called ‘CD70 low’, which means it is a low expression of CD70 protein. In this case, the treatment becomes very difficult because the amended immune cells (Car-T or other) do not find enough “key” to know the purpose. The researchers believe that the new treatment supply70-NKT is characteristic because it can attack the crops, even if the CD70 is present in very small quantities, which goes beyond this defensive trick that uses some types of cancer. And in the second step; It decomposes the protective environment of the crop that is full of immune cells that impede the ability of the immune system to move freely. Finally, it gets rid of the directed immune cells for CD70, which can usually lead to the rejection of treatment, which allows engineering cells to remain longer in the patient’s body and their combat work can continue. According to the author who participated in the study, Lily Yang, professor of microbiology and immunology at the University of California, and the supervisor participating in the research did not remain in the body forever, reducing the risk of long -term complications, such as chronic immunity inhibitors or bait rejections. The researchers emphasized that this approach can provide a safer and more effective treatment as it attacks the crop at the same time of different angles, and that patients with the distribution of kidney cancer can give a new life opportunity if it proves its success in clinical trials.